SYNTHETIC RECORD, NOT A REAL MEDICAL RECORD — Progress Note 2 — Focused Visit (Follow-up) — Friedrich Nietzsche

PatientFriedrich Nietzsche
Date of birth1989-10-15
IdentifiersMRN HR-NI019-SYN; SSN (made up) 000-19-5523
Document date2026-07-21
AuthorKonrad Ellison-Mbatha, MD
CustodianSt. Posthumous Health Center

Readable copy of the C-CDA narrative, generated with the XML. Coded entries are in the XML file beside this page.

Chief Complaint

Two-week review of the headache diary, the MRI and the eye examination, seen the same day by headache medicine. [S]

History of Present Illness

Mr. Nietzsche returns with his 14-day headache diary, after an MRI and blood tests this morning and a comprehensive eye examination, and is seen by Dr. Achterberg-Sato of headache medicine on the same day. His diary shows headache on 10 of 14 days. On 7 of them the pain was moderate or severe, throbbing, mostly over the right forehead and eye, worse with walking uphill or reading, with light and noise sensitivity and nausea, and vomiting on 3; it lasted from six hours to most of two days. On the other 3 days the headache was a milder pressure across the forehead. He has had no visual or other aura. He took the butalbital combination on 9 days, two or three tablets each time, and ibuprofen on 2 more, so acute medicine on 11 of 14 days. By his account he has had headache on about 20 days a month for at least eight months, and has taken the combination tablets on most of those days. He has slept four to five hours a night. He has had no weakness, numbness, fever or change in his usual vision. [S]

ElementDetail
DiaryHeadache on 10 of 14 days, 7 with migraine features; vomiting on 3; no aura
Acute medicineButalbital combination on 9 days, ibuprofen on 2: 11 of 14 days
Duration of the patternAbout 20 headache days a month for at least eight months
MRINormal brain; high myopia of the globes
Syphilis serologyTreponemal antibody 0.12 (nonreactive); RPR nonreactive
Eye examinationPathologic myopia of the right eye; no retinal break; pressures 15 and 14

Review of Systems

SystemResultFinding
ConstitutionalNegativeNo fever or weight loss
EyesPositivePoor right eye as always; tired eyes when reading; no new visual loss, flashes or floaters
GastrointestinalPositiveNausea with attacks, vomiting on 3 days; occasional constipation
NeurologicalPositiveHeadaches as in the diary; no weakness, numbness, speech change or aura
PsychiatricNegativeFrustrated by lost working days; no hopelessness or thoughts of self-harm

5 systems reviewed. [S]

Medications

MedicationFrequencyRouteDatesStatusEvidence
Butalbital 50 mg, acetaminophen 325 mg and caffeine 40 mg oral tablet, one or two tablets as needed for headache, taken on about 16 days a month, up to four tablets a day (prescribed abroad)One or two tablets as needed, about 16 days a month, up to four a dayOral route2025-11-03 to 2026-07-21stoppedS
Ibuprofen 200 mg oral tablet, two tablets as needed for headache on days without the combination tablets, about 4 days a month (over the counter)Two tablets as needed, about 4 days a monthOral route2025-11-03 to 2026-07-21stoppedS
Butalbital 50 mg, acetaminophen 325 mg and caffeine 40 mg oral tablet, scheduled taper: one tablet twice a day for 7 days, then one tablet a day for 7 days, then one tablet every other day for 7 days, then stopScheduled taper over three weeks: twice a day, then once a day, then every other day, then stop; not for extra dosesOral route2026-07-21 to 2026-08-10completedS
Naproxen 500 mg oral tablet, one tablet with food at the start of a migraine attack, may repeat once after 12 hours; no more than two days a weekOne tablet at attack onset, may repeat once after 12 hours; no more than two days a weekOral route2026-07-21activeS
Metoclopramide 10 mg oral tablet, one tablet with the acute medicine when a migraine attack brings nausea or vomiting; no more than two days a weekOne tablet with the acute medicine when nausea is present, no more than once a dayOral route2026-07-21activeS
Galcanezumab 120 mg/mL auto-injector, 240 mg (two injections) under the skin as a first loading dose, then 120 mg once a month, for chronic migraine preventionLoading dose of 240 mg (two injections) on the first day, then 120 mg every four weeksSubcutaneous route2026-07-21activeS

Allergies and Intolerances

AllergyReactionStatusEvidence
No known allergyactiveS

Vital Signs

DateMeasureValueUnitProvenance
2026-07-21Body height174cmS
2026-07-21Body weight66.2kgS
2026-07-21Body mass index (BMI) [Ratio]21.9kg/m2S
2026-07-21Systolic blood pressure116mm[Hg]S
2026-07-21Diastolic blood pressure74mm[Hg]S
2026-07-21Heart rate66/minS
2026-07-21Respiratory rate14/minS
2026-07-21Body temperature36.5CelS
2026-07-21Oxygen saturation in Arterial blood by Pulse oximetry98%S

Results

DateMeasureValueUnitReference rangeFlagProvenance
2026-07-21Treponema pallidum Ab [Measurement] in Serum0.12{index_val}Below 0.90: nonreactiveNormalS
2026-07-21Right eye Intraocular pressure15mm[Hg]10-21 mmHgNormalS
2026-07-21Left eye Intraocular pressure14mm[Hg]10-21 mmHgNormalS

Physical Exam

Vital signs recorded on 2026-07-21; see the Vital Signs section. [S]

SystemFinding
GeneralComfortable today; blood pressure 116/74, pulse 66
EyesRight pupil about 1 mm larger than the left in light and dark, both reacting briskly, no afferent defect, no ptosis; eye movements full; at the eye examination today, best corrected vision 20/100 right and 20/20 left, refraction about -13.50 right and -6.25 left, pressures 15 and 14 mmHg, and on dilated examination a tilted right disc with peripapillary atrophy, a posterior staphyloma and patchy chorioretinal atrophy at the right macula, no choroidal neovascularization on OCT, a tessellated left fundus, and no retinal breaks or lattice in either eye
NeurologicalCranial nerves otherwise normal; strength, sensation, reflexes, coordination and gait normal; no papilledema
Head and neckTenderness of the right occipital and neck muscles; temporal arteries normal

Problems

ProblemClinical statusVerificationCodeProvenance
Frequent disabling headaches on about 20 days a month, with nausea, vomiting and light sensitivity, mostly right-sided, since childhood and more frequent over the past year, with a combination headache tablet containing butalbital taken on about 16 days a month; under evaluation with a headache diary, MRI, syphilis serology and a headache medicine consultationresolvedconfirmed R51.9S — Synthetic presenting problem anchored to his documented headaches; superseded when the consultation confirmed chronic migraine with medication overuse headache.
Chronic migraine without aura (15 or more headache days a month for more than three months, at least 8 with migraine features); ICHD-3 criteria met in a two-week diary; MRI of the brain normal; synthetic modern diagnosis linked to his documented headaches, which historians interpret differentlyactiveconfirmed G43.709S — Synthetic modern diagnosis made at the consultation; the historical diagnosis is disputed (CLM-0014), so this is not a claim about his real diagnosis.
Medication overuse headache from a butalbital, acetaminophen and caffeine combination on 10 or more days a month for more than three months, with ibuprofen on other days; resolved after a three-week taper and withdrawalactiveconfirmed G44.40S — Synthetic diagnosis made at the consultation, anchored to his documented use of many medicines and sedatives; not a claim about his real medicines.
High myopia in both eyes, much worse in the right eye, since early childhood, with long-standing poor vision in the right eye and unequal pupils; comprehensive eye examination bookedactiveconfirmed H52.13S — Synthetic modern coding of his documented severe myopia.
Pathologic (degenerative) myopia of the right eye with patchy chorioretinal atrophy of the macula, a posterior staphyloma and a tilted optic disc; no choroidal neovascularization on OCT; best corrected vision 20/100 in the right eyeactiveconfirmed H44.2E1S — Synthetic finding of the comprehensive eye examination, anchored to his documented poor right eye and the retrospective reading of it as myopic degeneration; not a claim about his real eyes.
Chronic insomnia, with difficulty falling asleep and early waking, worse on headache nights; no sleep medicine at intakeactiveconfirmed G47.00S — Synthetic sleep problem anchored to his documented severe insomnia; not a claim about his real sleep.

Assessment and Plan

Protocol monitoring: items the monitoring protocol calls for at this visit. [S]

DomainMeasureIntervalStatusDetail
ExaminationRed-flag screen (SNNOOP10): systemic signs, neurological signs, sudden onset, onset after 50, change in pattern, positional or Valsalva features, papilledema, progressive courseEvery visitCompleted todayStrong right-sided predominance and a change in frequency prompted imaging; MRI normal; no other red flags; no papilledema
SurveyHeadache diary: headache days, migraine days, attack features, triggersEvery visitCompleted today14 days kept: headache on 10, migraine features on 7; about 20 headache days a month by history for at least eight months
Medication safetyAcute-medicine days (overuse limits: combination analgesics, triptans fewer than 10 days a month, simple analgesics fewer than 15)Every visitCompleted todayAcute medicine on 11 of 14 days: butalbital combination on 9, ibuprofen on 2
ImagingMRI of the brain with and without contrastOnce, for the change in frequency, strong right-sided predominance, unequal pupils and a poor right eyeCompleted todayDone this morning: normal brain, pituitary and optic nerves; elongated globes with a right posterior staphyloma
LaboratorySyphilis serology (treponemal immunoassay and RPR)Once, at diagnosisCompleted todayDrawn this morning: treponemal antibody 0.12 (nonreactive) and RPR nonreactive; no lumbar puncture needed
ExaminationComprehensive eye examination: refraction, pupils, pressure, dilated fundus examination, macular OCTAt diagnosis, then yearly for pathologic myopia, and urgently for new flashes, floaters or a shadowCompleted todayPathologic myopia of the right eye with macular atrophy; no neovascularization or retinal break; intraocular pressure 15 mmHg right and 14 mmHg left
Medication safetyBarbiturate withdrawal: tremor, sweating, agitation, insomnia, confusion, seizures; rebound headacheDuring the three-week taper and at the first visit after itCompleted todayBefore the taper: no history of seizures, no alcohol excess and no other sedatives; taper explained in writing
Medication safetyGalcanezumab tolerability: injection sites, constipation, blood pressure, hypersensitivityBefore starting and at each injection visitCompleted todayBefore the first dose: blood pressure 116/74; no allergy; occasional constipation noted; injection technique taught and the loading dose given in clinic
ExaminationPreventive efficacy (at least 50% fewer monthly migraine days; headache days below 15 a month)At three months on treatmentDueGalcanezumab started today; efficacy judged at about three months
SurveyDisability (MIDAS, recorded as its five items, and HIT-6)At baseline and after two to three months of treatmentUp to dateMIDAS 74 (grade IV) and HIT-6 68 at intake; repeat at about two to three months
SurveyMood (PHQ-9) and anxiety (GAD-7), with direct questions about hopelessness and self-harmAt baseline and at two to three months; questions at every visitUp to datePHQ-9 7 and GAD-7 6 at intake; no hopelessness or thoughts of self-harm today
Self-managementSleep: hours, sleep diary, insomnia severity; no sedative sleeping tabletsEvery visitOrderedFour to five hours a night; CBT-I booked to start next week
Self-managementReading, writing and walking planEvery visitCompleted todayReading in short spells with breaks; daily walks continue
ReferralHeadache medicine consultationAt diagnosisCompleted todaySeen by Dr. Achterberg-Sato today

Goal progress:

Guideline basis: Headache Classification Committee of the International Headache Society (IHS). The International Classification of Headache Disorders, 3rd edition (2018); The American Headache Society Consensus Statement: Update on integrating new migraine treatments into clinical practice (2021); Calcitonin gene-related peptide-targeting therapies are a first-line option for the prevention of migraine: An American Headache Society position statement update (2024); European Academy of Neurology guideline on the management of medication-overuse headache (2020); European Headache Federation guideline on the use of monoclonal antibodies targeting the calcitonin gene related peptide pathway for migraine prevention - 2022 update (2022); Choosing wisely in headache medicine: the American Headache Society's list of five things physicians and patients should question (2013); Sexually Transmitted Infections Treatment Guidelines, 2021 (2021); Refractive Errors Preferred Practice Pattern (2023); Comprehensive Adult Medical Eye Evaluation Preferred Practice Pattern (2026); Behavioral and psychological treatments for chronic insomnia disorder in adults: an American Academy of Sleep Medicine clinical practice guideline (2021)

Follow-up: Nurse phone check at the end of the first taper week. Four-week review with the second galcanezumab injection. Call the same day for withdrawal symptoms, a headache unlike his usual attacks, weakness, numbness, fever, or new flashes or floaters. Next scheduled visit 2026-08-18: four-week review after starting galcanezumab and the taper: withdrawal, headache days, acute medicine and the second injection. [S]